Clinical Trial Detail

NCT ID NCT02426723
Title Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors JW Pharmaceutical
Indications

multiple myeloma

Therapies

CWP232291

Dexamethasone + Lenalidomide

Age Groups: adult

No variant requirements are available.